Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• Age > 18

• Hospitalized for peritoneal catheter placement for peritoneal dialysis

Exclusion Criteria:

• Pregnancy

• Hiperkalemia (K> 5.5meq/l)

• Intolerance to spironolactone